The Life Sciences team advised PreDICTA Biosciences on raising an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand PreDICTA’s team and CLIA-approved lab infrastructure, and advance commercialization of the company’s first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases. In addition to the successful raise, PreDICTA also announced the appointment of Brian McKernan as CEO.
Goodwin has served as PreDICTA's counsel since its inception.
Founded by leading cancer genomics researchers and clinicians, PreDICTA is a precision oncology company developing novel diagnostic and therapeutic products. The company’s non-invasive diagnostics initially focus on multiple myeloma, equipping physicians with the unique ability to determine the likelihood of a patient responding to immunotherapies. PreDICTA’s mission is to overcome the numerous limitations in the diagnosis and prognosis of common blood cancers and autoimmune diseases.
The Goodwin deal was led by Mayan Katz and Micaiah Barley and included Grace Kim and Christina Lewis, with invaluable assistance from Matt Wetzel, Roger Cohen, Rebecca Kennedy, Aniko Bouley and Allison Goldsher.
For more information on the deal, please read the press release.